Zeltia S.A. (ZEL SM; ZEL MC) today presented its financial results for the first quarter of 2006, which showed a significant increase in Research & Development (R&D) spend, to 11.8 million euros. This represents a 32% increase compared to the same period in 2005. Zeltia’s PharmaMar subsidiary accounted for most of that sum, at 9.5 million euros (+25% compared to last year) while Neuropharma reported expenditure of 1.9 million euros (+90%) in R&D.
